All In Biotech

Drug Trial Radar · NCT03298451

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,324 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,324

Actual

Start

Oct 11, 2017

Primary completion

Aug 27, 2021

Study completion Dec 31, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy

Conditions

  • Hepatocellular Carcinoma

Interventions

  • DurvalumabDrug

    Durvalumab IV (intravenous infusion).

  • Tremelimumab (Regimen 1)Drug

    Tremelimumab IV (intravenous infusion).

  • Tremelimumab (Regimen 2)Drug

    Tremelimumab IV (intravenous infusion).

  • SorafenibDrug

    Sorafenib, as per standard of care

  • Durvalumab (Regimen 1)Drug

    Durvalumab IV (intravenous infusion).

  • Durvalumab (Regimen 2)Drug

    Durvalumab IV (intravenous infusion).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mgTime frame: From the date of randomization until death due to any cause, assessed up to the data cut-off date (27Aug2021, to a maximum of approximately 46 months).

Locations

160 sites in 17 countries. Site status is shown where the registry gives one.

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    San Francisco, California

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Westwood, Kansas

  • Research Site

    Baltimore, Maryland

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    New York, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Portland, Oregon

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Dallas, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Murray, Utah

  • Research Site

    Barretos, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Florianópolis, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Hamilton, Ontario, Canada

  • Research Site

    Kingston, Ontario, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Sherbrooke, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Changchun, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Dalian, China

Showing 40 of 160 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.